The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Is Transduced into Cellular Responses in Neurons: Ca2+ Signals and Neurotransmitter Release

Molecular Pharmacology

Volumn 64, Issue 5, 2003, Pages 1217-1226

  Dajas Bailador, Federico A ^a   Heimala, Kaisa ^a   Wonnacott, Susan ^a  

^a University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; LIGAND; MECAMYLAMINE; NEUROTRANSMITTER; NICOTINE; NICOTINIC RECEPTOR; NORADRENALIN; POTASSIUM CHLORIDE; RECEPTOR SUBTYPE; RIVASTIGMINE;

ALLOSTERISM; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN SLICE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; ELECTROPHYSIOLOGY; ENZYME ACTIVITY; ENZYME INHIBITION; LIGAND BINDING; MALE; NERVE CELL; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SYNAPTIC MEMBRANE;

ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; CALCIUM SIGNALING; CHOLINESTERASE INHIBITORS; GALANTAMINE; HIPPOCAMPUS; MALE; NEURONS; NEUROTRANSMITTER AGENTS; NICOTINE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SYNAPTIC TRANSMISSION; TRITIUM;

EID: 0142247220     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.5.1217     Document Type: Article

References (43)

1. 3H]norepinephrine from rat brain slices using a new 96-well format assay. Neuropharmacology 39:2663-2672.
2. Berridge MJ, Bootman MD, and Lipp P (1998) Calcium: a life and death signal. Nature (Lond) 395:645-648.
3. 50) of an enzymatic reaction. Biochem Pharmacol. 22:3099-3108.
4. 3H]-dopamine release. Br J Pharmacol 117:595-606.
5. Cooper JC, Gutbrod O, Witzemann V, and Methfessel C (1996) Pharmacology of the nicotinic acetylcholine receptor from fetal rat muscle expressed in Xenopus oocytes. Eur J Pharmacol 309:287-298.
6. Cooper ST, Harkness PC, Baker ER, and Millar NS (1999) Up-regulation of cell-surface α4β2 neuronal nicotinic receptors by lower temperature and expression of chimeric subunits. J Biol Chem 274:27145-27152.
7. Cooper ST and Millar NS (1997) Host cell-specific folding and assembly of the neuronal nicotinic acetylcholine receptor α7 subunit. J Neurochem 68:2140-2151
8. 2+ stores. J Neurochem 81:606-614.
9. Dajas-Bailador FA, Soliakov L, and Wonnacott S (2002b) Nicotine activates the extracellular signal-regulated kinase 1/2 via the α7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones. J Neurochem 80:520-530.
10. 3H]methyllycaconitine: a new radioligand for labeling α7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 38:679-690.
11. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, and Sweatt JD (2001) β-amyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21:4125-4133.
12. Ellman GL, Courtney KD, Andres JV, and Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
13. Katsuki H, Izumi Y, and Zorumski CF (1997) Noradrenergic regulation of synaptic plasticity in the hippocampal CA1 region. J Neurophysiol 77:3013-3020.
14. Kulak JM, McIntosh JM, Yoshikami D, and Olivera BM (2001) Nicotine-evoked transmitter release from synaptosomes: functional association of specific presynaptic acetylcholine receptors and voltage-gated calcium channels. J Neurochem 77:1581-1589.
15. 3H]norepinephrine from developing and adult rat hippocampus: direct and indirect mechanisms. Neuropharmacology 42:653-661.
16. Levin ED (2000) The role of nicotinic acetylcholine receptors in cognitive function, in Neuronal Nicotinic Receptors (Clementi F, Fornasari D, Gotti C eds) pp 587-595, Springer-Verlag, Berlin.
17. Lukas RJ, Norman SA, and Lucero L (1993) Characterisation of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line. Mol Cell Biol 4:1-12.
18. Maelicke A, Schrattenholz A, Samochocki M, Radina M, and Albuquerque EX (2000) Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 113:199-206.
19. Palmer AM (1996) Neurochemical studies of Alzheimer's disease. Neurodegeneration 5:381-391.
20. Peng X, Katz M, Gerzanich V, Anand R, and Lindstrom J (1994) Human α7 acetylcholine receptor: cloning of the α7 subunit from SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional α7 homomers expressed in Xenopus oocytes. Mol Pharmacol 45:546-554.
21. Pereira EF, Alkondon M, Reinhardt S, Maelicke A, Peng X, Lindstrom J, Whiting P, and Albuquerque EX (1994) Physostigmine and galantamine: probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 270:768-778.
22. Pereira EF, Hilmas C, Santos MD, Alkondon M, Maelicke A, and Albuquerque EX (2002) Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 53:479-500.
23. Pereira EF, Reinhardt-Maelicke S, Schrattenholz A, Maelicke A, and Albuquerque EX (1993) Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons. J Pharmacol Exp Ther 265:1474-1491.
24. Perry EK, Smith CJ, Court JA, Bonham JR, Rodway M, and Atack JR (1988) Interaction of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro. Neurosci Lett 91:211-216.
25. Radcliffe KA and Dani JA (1998) Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J Neurosci 18:7075-7083.
26. Rathouz MM and Berg DK (1994) Synaptic-type acetylcholine receptors raise intracellular calcium levels in neurons by two mechanisms. J Neurosci 14:6935-6945.
27. Ridley DL, Pakkanen J, and Wonnacott S (2002) Effects of chronic drug treatments on increases in intracellular calcium mediated by nicotinic acetylcholine receptors in SH-SY5Y cells. Br J Pharmacol 135:1051-1059.
28. Ridley DL, Rogers A, and Wonnacott S (2001) Differential effects of chronic drug treatment on α3* and α7 nicotinic receptor binding sites, in hippocampal neurones and SH-SY5Y cells. Br J Pharmacol 133:1286-1295.
29. Sacaan AI, Dunlop JL, and Lloyd GK (1995) Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. J Pharmacol Exp Ther 274:224-230.
30. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EFR, et al. (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmcol Exp Ther 305:1024-1036.
31. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, and Albuquerque EX (2002) The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61:1222-1234.
32. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, and Maelicke A (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 49:1-6.
33. Sharples CG, Karig G, Simpson GL, Spencer JA, Wright E, Millar NS, Wonnacott S, and Gallagher T (2002) Synthesis and pharmacological characterization of novel analogues of the nicotinic acetylcholine receptor agonist (+/-)-UB-165. J Med Chem 45:3235-3245.
34. Sharples CG, Kaiser S, Soliakov L, Marks MJ, Collins AC, Washburn M, Wright E, Spencer JA, Gallagher T, Whiteaker P, et al. (2000) UB-165: A novel nicotinic agonist with subtype selectivity implicates the α4β 2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J Neurosci 20:2783-2791.
35. Shaw KP, Aracava Y, Akaike A, Daly JW, Rickett DL, and Albuquerque EX (1985) The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor ion channel complex. Mol Pharmacol 28:527-538.
36. Storch A, Schrattenholz A, Cooper JC, Abdel GE, Gutbrod O, Weber KH, Reinhardt S, Lobron C, Hermsen B, and Soskic V (1995) Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells. Eur J Pharmacol 290:207-219.
37. Vaughan PFT, Peers C, and Walker JH (1997) The regulation of noradrenaline release by receptors and second messengers in the human neuroblastoma clone SH-SY5Y. Curr Top Neurochem 1:195-209.
38. Vizi ES and Kiss JP (1998) Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions. Hippocampus 8:566-607.
39. Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, and Lindstrom J (1996) Assembly of human neuronal nicotinic receptor α5 subunits with α3, β2 and β4 subunits. J Biol Chem 271:17656-17665.
40. Wilkie GI, Hutson P, Sullivan JP, and Wonnacott S (1996) Pharmacological characterization of a nicotinic autoreceptor in rat hippocampal synaptosomes. Neurochem Res 21:1141-1148.
41. Wonnacott S (1997) Presynaptic nicotinic ACh receptors. Trends Neurosci 20:92-98.
42. Woodruff-Pak DS, Lander C, and Geerts H (2002) Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 8:405-426.
43. Zwart R, Kleef RG, Gotti C, Smulders CJ, and Vijverberg HP (2000) Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs. J Neurochem 75:2492-2500.